FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

NCT06636682 | Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: FK-PC101-01
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 3

Brief Summary

The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are: Does FK-PC101 delay or prevent the return of prostate cancer following surgery? What medical problems do participants (subjects) have when taking FK-PC101? Researchers will compare FK-PC101 to current treatment practice to see if FK-PC101 works to prevent or delay the return of prostate cancer following surgery to remove the prostate cancer tumor. Subjects will: Have a sample of the prostate cancer tissue collected at the time of surgery to remove this tissue from the body. This tissue will then be used to create a personalized vaccine that is specific to your prostate cancer. If randomly selected to receive the vaccine, subjects will receive the vaccine up to 7 times over a 6-month period. In addition to the treatment visits for those randomized to receive FK-PC101, there will be up to 4 follow up visits to the clinic over a 22-month (nearly 2 year) period. For subjects randomized to receive current treatment practice, they will be asked to attend up to 8 visits over 22 months to track if there is any detectable cancer. Should their prostate cancer return within a year following surgery, they will be eligible to receive FK-PC101, which already had been produced and thus no additional tumor tissue would need to be obtained. Subjects in both study arms will have regular blood tests and scans to test whether their prostate cancer has returned.

Conditions

Prostate Cancer (Adenocarcinoma); Prostate CA; Prostate Cancers; Prostate Cancer (Post Prostatectomy); Prostate Cancer; Prostate Cancer Patients Undergoing Radical Prostatectomy; High-risk Prostate Cancer

Keywords

Vaccine; Prostatectomy; Autologous; Radical Prostatectomy

Outcome Measures

Primary Outcomes (1)

• Disease-free survival (DFS)

  DFS is defined as local prostate cancer recurrence, distant metastatic prostate cancer recurrence, biochemical recurrence of PSA, or death from any cause

  Up to approximately 22 months

Secondary Outcomes (4)

• Time to next treatment (TTNT)

  Up to approximately 22 months

• Metastasis-free survival (MFS)

  Up to approximately 22 months

• Immune response to FK-PC101

  From baseline until Month 22

• Safety and tolerability of FK-PC101

  Up to approximately 22 months

Other Outcomes (1)

• Overall survival (OS)

  Up to approximately 22 months

Study Arms (2)

FK-PC101

EXPERIMENTAL

Up to 7 doses of intradermal FK-PC101 vaccine

Biological: FK-PC101

Standard of Care

ACTIVE COMPARATOR

Standard of care, with possibility to cross-over to FK-PC101 vaccine should prostate cancer recur within 1 year of radical prostatectomy

Biological: Standard of Care (SOC)

Interventions

FK-PC101 BIOLOGICAL

Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).

FK-PC101

Standard of Care (SOC) BIOLOGICAL

Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).

Standard of Care

Eligibility Criteria

• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Has localized high-risk or very high-risk prostate cancer based on the NCCN v4.2023 classification.
• Has ≥3 prostate biopsy cores with ≥50% tumor involvement.
• Has PSA \>4 ng/mL ≤28 days prior to enrollment.
• Has no evidence of distant metastases based on PSMA-PET/CT performed ≤28 days prior to enrollment.
• Is a candidate for radical prostatectomy, and scheduled radical prostatectomy date must be 3 to 14 days after enrollment.
• Has not received nor plans to receive neoadjuvant (preoperative) radiation therapy, androgen deprivation therapy (ADT), or any other anticancer therapy.
• Has a life expectancy \>5 years.
• Stage \>pT3a (tumor has extended outside of the prostate on one side).
• Gleason score of 8, 9, or 10 (high/very high) on prostatectomy specimen.
• Subjects with pT3b or pT4 tumors with a Gleason sum 7 (4+3) are eligible.
• Pelvic lymph node dissection (PLND) is required with either pN0 or pN1 nodal staging permitted.
• Subjects must have negative surgical margins or microscopic-only positive surgical margins.
• Final eligibility criteria at 2 months postoperative for randomization include:
• FK-PC101 has been produced for the subject and meets all release specifications.
• An undetectable PSA (\<0.04 ng/mL) on the most recent test performed prior to randomization (Day -4 to -7).

You may not qualify if:

• Has an additional active malignancy that may confound the assessment of the study endpoints. If the subject has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the Sponsor before study entry. Note: Subjects with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including breast DCIS, transitional cell carcinoma/NMIBC, anal carcinoma, and melanoma in situ).
• Is eligible for and elects to receive adjuvant therapy following RP.
• Has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association \[NYHA\] Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina, pulmonary embolism or stroke within 6 months prior to study entry, uncontrolled hypertension, or clinically significant arrhythmias not controlled by medication).
• Has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the subject at significant risk for pulmonary complications during the study.
• Has known metastases, such as bone, visceral, or brain or leptomeningeal metastases.
• Has an active autoimmune disease or Grade ≥3 pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbamazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.
• Is currently receiving systemic steroid therapy at a prednisone equivalent dose of \>10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to enrollment.
• Has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
• Is at risk for disseminated BCG infection or has previously demonstrated an allergic response to BCG or its components.
• Has known positive status for human immunodeficiency virus (HIV) or active or chronic Hepatitis (Hep) B or Hep C. Screening is not required.
• Has any medical condition which in the opinion of the Investigator places the subject at an unacceptably high risk for toxicity.

Sponsors & Collaborators

• Cellvax Therapeutics Inc: lead

Study Sites (3)

University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic

Chicago, Illinois, 60637, United States

ACTIVE NOT RECRUITING

Central Ohio Urology Group

Gahanna, Ohio, 43230, United States

RECRUITING

Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States

RECRUITING

MeSH Terms

Conditions

Prostatic Neoplasms; Adenocarcinoma

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Fernando Kreutz, MD PhD

  Cellvax Therapeutics Inc

  STUDY CHAIR

Central Study Contacts

FK-PC101 Trial Management

CONTACT

215-941-5916; FKPC101@cellvx.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 8, 2024
• First Posted: October 15, 2024
• Study Start: October 14, 2024
• Primary Completion (Estimated): February 2, 2027
• Study Completion (Estimated): May 4, 2027
• Last Updated: October 21, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)